Article Sidebar

PDF (Tiếng Việt)
Published: 2025-03-26
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v188i3.3121
Issue
Vol. 188 No. 3 (2025)
Section
Các bài báo
How to Cite
Dũng, N. T. ., Loan, T. T. ., Hà, C. T. N. ., & Long, Đường M. . (2025). Assessment of arteriovenous fistula survival and related factors in hemodialysis patients with autologous vascular access complications. Journal of Medical Research, 188(3), 83-94. https://doi.org/10.52852/tcncyh.v188i3.3121

Assessment of arteriovenous fistula survival and related factors in hemodialysis patients with autologous vascular access complications

Nghiem Trung Dung, To Thi Loan, Chu Thi Ngoc Ha, Duong Manh Long

Main Article Content

Abstract

A cross-sectional study was conducted on 172 patients with autologous vascular access complications at Bach Mai Hospital and Hanoi Kidney Hospital to determine the functional life of autologous arteriovenous fisstula (AVF) and factors affecting this condition. The average functional life of patients was 48.02 ± 46.13 months (median value was 36 months). Thrombosis was the leading cause of vascular access dysfunction (accounting for 55.23%). Clinical parameters affecting the functional life of AVF included: history of diabetes, hypertension, age at AVF surgery, surgical site, dialysis facilities and history of AVF intervention (p < 0.05). Anemia (hemoglobin ≤ 80 g/L), thrombocytosis (≥ 245 G/L) and transferrin saturation deficiency were also associated with reduced functional life of autologous vascular access (p < 0.05).

Article Details

Keywords

Vascular access, arteriovenous fistula survival, hemodialysis

References

1. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7-11. doi:10.1016/j.kisu.2021.11.003
2. Jager KJ, Kovesdy C, Langham R, et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96(5):1048-1050. doi:10.1016/j.kint.2019.07.012
3. Bello AK, Okpechi IG, Osman MA, et al. Epidemiology of haemodialysis outcomes. Nat Rev Nephrol. 2022;18(6):378-395. doi:10.1038/s41581-022-00542-7
4. Djajakusumah TM, Hapsari P, Nugraha P, et al. Characteristics of Vascular Access Cannulation Complications in End Stage Kidney Disease Patients in West Java from 2018 to 2022: A Retrospective Observational Study. IJNRD. 2024;17:47-58. doi:10.2147/IJNRD.S440467
5. Allon M. Vascular Access for Hemodialysis Patients: New Data Should Guide Decision Making. Clin J Am Soc Nephrol. 2019;14(6):954-961. doi:10.2215/CJN.00490119
6. CDC. About Body Mass Index (BMI). BMI. July 17, 2024. Accessed December 8, 2024. https://www.cdc.gov/bmi/about/index.html
7. Moawad MA, Hassan W. Update in Hypertension: The Seventh Joint National Committee Report and Beyond. Ann Saudi Med. 2005;25(6):453-458. doi:10.5144/0256-4947.2005.453
8. Cappellini MD, Motta I. Anemia in Clinical Practice-Definition and Classification: Does Hemoglobin Change With Aging? Semin Hematol. 2015;52(4):261-269. doi:10.1053/j.seminhematol.2015.07.006
9. Sulowicz W, Radziszewski A. Pathogenesis and treatment of dialysis hypotension. Kidney International. 2006;70:S36-S39. doi:10.1038/sj.ki.5001975
10. Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1-S164. doi:10.1053/j.ajkd.2019.12.001
11. Wen M, Li Z, Li J, et al. Risk Factors for Primary Arteriovenous Fistula Dysfunction in Hemodialysis Patients: A Retrospective Survival Analysis in Multiple Medical Centers. Blood Purif. 2019;48(3):276-282. doi:10.1159/000500045
12. Al-Jaishi AA, Liu AR, Lok CE, et al. Complications of the Arteriovenous Fistula: A Systematic Review. J Am Soc Nephrol. 2017;28(6):1839-1850. doi:10.1681/ASN.2016 040412
13. Puskar D, Pasini J, Savić I, et al. Survival of primary arteriovenous fistula in 463 patients on chronic hemodialysis. Croat Med J. 2002;43(3):306-311.
14. Wongmahisorn Y. Survival and Prognostic Predictors of Primary Arteriovenous Fistula for Hemodialysis. Ann Vasc Dis. 2019;12(4):493-499. doi:10.3400/avd.oa.19-00058
15. Chang TI, Paik J, Greene T, et al. Intradialytic hypotension and vascular access thrombosis. J Am Soc Nephrol. 2011;22(8):1526-1533. doi:10.1681/ASN.2010101119
16. Hu H, Patel S, Hanisch JJ, et al. Future research directions to improve fistula maturation and reduce access failure. Semin Vasc Surg. 2016;29(4):153-171. doi:10.1053/j.semvascsurg.2016.08.005
17. Paneni F, Beckman JA, Creager MA, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013;34(31):2436-2443. doi:10.1093/eurheartj/eht149
18. Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc Disord. 2015;15:130. doi:10.1186/s12872-015-0124-z
19. Lee T, Thamer M, Zhang Q, et al. Vascular Access Type and Clinical Outcomes among Elderly Patients on Hemodialysis. Clin J Am Soc Nephrol. 2017;12(11):1823-1830. doi:10.2215/CJN.01410217
20. Brahmbhatt A, Remuzzi A, Franzoni M, et al. The molecular mechanisms of hemodialysis vascular access failure. Kidney Int. 2016;89(2):303-316. doi:10.1016/j.kint.20 15.12.019
21. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018
22. Moon JY, Lee HM, Lee SH, et al. Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis. Kidney Res Clin Pract. 2015;34(1):41-46. doi:10.1016/j.krcp. 2015.02.001